Clinical trial · Observational
ALBI and PALBI Scores and HCC Prognosis
Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities
NCT05720195CI-TRIAL-00063805completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores. To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) Prognosis | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ALBI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score
- timeFrame
- 2 years
- description
- We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
- measure
- Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score
- timeFrame
- 2 years
- description
- We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
Secondary outcomes (2)
- measure
- Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: • The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels. Exclusion Criteria: * Patients below 18 years old. * Patients with pre-existing other malignancies. * Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases. * Patients with pre-existing haematologic disorders. * Patients with proteinuria. * Missed follow-up.
References
Publications (0)
Data not yet available
No reference posted for this study.